Wells Fargo Maintains Overweight on Biomarin Pharmaceutical, Raises Price Target to $115
Portfolio Pulse from Benzinga Newsdesk
Wells Fargo analyst Mohit Bansal maintains an Overweight rating on Biomarin Pharmaceutical (NASDAQ:BMRN) and raises the price target from $110 to $115.
June 27, 2024 | 3:20 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Wells Fargo analyst Mohit Bansal maintains an Overweight rating on Biomarin Pharmaceutical and raises the price target from $110 to $115.
The raised price target and maintained Overweight rating from a reputable analyst at Wells Fargo is likely to positively impact Biomarin Pharmaceutical's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100